TABLE 1.
Characteristics of All Enrolled Patients (Cohort A) and Those Who Were Sampled During Bronchiectasis Exacerbations (Cohort B)
| Parameters | Cohort A (n = 119) | Cohort B (n = 58) | P Valuea |
|---|---|---|---|
| Age, y | 44.46 (14.34) | 44.27 (14.35) | .93 |
| Male sex, No. (') | 42 (35.29) | 20 (34.48) | .92 |
| BMI, kg/m2 | 20.24 (3.16) | 19.84 (2.98) | .43 |
| Bronchiectasis severity index | 6.73 (3.96) | 7.14 (4.45) | .54 |
| Baseline spirometry | |||
| FEV1, L | 1.83 (0.74) | 1.69 (0.69) | .24 |
| FEV1 ' predicted | 64.90 (23.04) | 62.66 (23.02) | .55 |
| FVC, L | 2.50 (0.85) | 2.42 (0.84) | .58 |
| FVC ' predicted | 74.55 (19.79) | 73.33 (21.06) | .95 |
| FEV1/FVC ' | 71.81 (14.06) | 69.11 (13.13) | .23 |
| Exacerbation frequency in the past 12 mo | 2 (1.00-3.00) | 2 (1.00-2.00) | .60 |
| Hospital admission in the past 12 mo | 0 (0.00-1.00) | 0 (0.00-1.00) | .66 |
| Modified Reiff score for chest HRCT scan | 7.55 (3.89) | 8.23 (3.95) | .28 |
| Pseudomonas aeruginosa colonization, No. (') | 43 (36.13) | 24 (41.38) | .50 |
| Treatment, No. (') | |||
| Inhaled corticosteroids | 15 (12.61) | 9 (15.52) | .60 |
| Macrolides | 41 (34.45) | 26 (44.83) | .18 |
| Influenza vaccination in last 12 mo | 1 (0.84) | 1 (1.72) | .61 |
Data are presented as mean (SD) or median (IQR) unless otherwise indicated. HRCT = high-resolution CT; IQR = interquartile range.
a
P values refer to comparisons between groups using χ2 test (categorical data), analysis of t test, or Mann-Whitney test, when appropriate.